Active, not recruitingPhase 3NCT04956692
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab SC(biological)
- Enrollment
- 531 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, United States
- St Joseph Heritage Healthcare-Oncology ( Site 0102), Fullerton, California, United States
- Cancer Blood and Specialty Clinic ( Site 0105), Los Alamitos, California, United States
- PIH Health Hematology Medical Oncology ( Site 0106), Whittier, California, United States
- Holy Cross Hospital ( Site 0017), Fort Lauderdale, Florida, United States
- Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104), Hollywood, Florida, United States
- Advent Health ( Site 0013), Orlando, Florida, United States
- Fort Wayne Medical Oncology and Hematology ( Site 0101), Fort Wayne, Indiana, United States
- Baptist Health Lexington ( Site 0099), Lexington, Kentucky, United States
- St Luke's Hospital - Kansas City ( Site 0033), Kansas City, Missouri, United States
- St. Vincent Frontier Cancer Center ( Site 0058), Billings, Montana, United States
- Montefiore Medical Center [Bronx, NY] ( Site 0040), The Bronx, New York, United States
- The University of Tennessee Medical Center ( Site 0050), Knoxville, Tennessee, United States
- Tennessee Oncology ( Site 0051), Nashville, Tennessee, United States
- Oncology Consultants, PA ( Site 0052), Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04956692 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital